Lymphocyte-predominant Hodgkin's disease in clinical stage IA: Interim analysis of treatment options in three study generations of the German Hodgkin study group (GHSG).

被引：0
|
作者：
Nogova, L
Reineke, T
Josting, A
Brillant, C
Eich, H
Wingbermuehle, K
Behringer, K
Diehl, V
Engert, A
机构：
[1] Univ Hosp Cologne, Clin Radiotherapy, Cologne, Germany
[2] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
82
引用
收藏
页码：26A / 27A
页数：2
相关论文
共 50 条
  • [21] Lymphocyte-Predominant Hodgkin's Disease in Children: A Case Study and Review of the Literature
    Stier, James R.
    Vasquez, Robert J.
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [22] Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group
    D A Eichenauer
    H Goergen
    A Plütschow
    D Wongso
    K Behringer
    S Kreissl
    I Thielen
    T Halbsguth
    P J Bröckelmann
    M Fuchs
    B Böll
    B von Tresckow
    P Borchmann
    A Engert
    Leukemia, 2016, 30 : 1425 - 1427
  • [23] Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Goergen, Helen
    Pluetschow, Annette
    Behringer, Karolin
    Kreissl, Stefanie
    Broeckelmann, Paul
    Fuchs, Michael
    Boell, Boris
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2015, 126 (23)
  • [24] Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group
    Eichenauer, D. A.
    Goergen, H.
    Pluetschow, A.
    Wongso, D.
    Behringer, K.
    Kreissl, S.
    Thielen, I.
    Halbsguth, T.
    Broeckelmann, P. J.
    Fuchs, M.
    Boell, B.
    von Tresckow, B.
    Borchmann, P.
    Engert, A.
    LEUKEMIA, 2016, 30 (06) : 1425 - 1427
  • [25] Positron Emission Tomography supported Treatment of early stage Hodgkin's Disease: Final Results of the German Hodgkin Study Group (GHSG)
    Frerker, Bernd
    Hildebrandt, Guido
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (05) : 488 - 488
  • [26] Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
    Dennis A. Eichenauer
    Annette Plütschow
    Michael Fuchs
    Sylvia Hartmann
    Martin-Leo Hansmann
    Boris Böll
    Bastian von Tresckow
    Peter Borchmann
    Andreas Engert
    Leukemia, 2020, 34 : 953 - 956
  • [27] Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Fuchs, Michael
    Hartmann, Sylvia
    Hansmann, Martin-Leo
    Boell, Boris
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    LEUKEMIA, 2020, 34 (03) : 953 - 956
  • [28] OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG)
    Borchmann, S.
    Mueller, H.
    Haverkamp, H.
    Baues, C.
    Markova, J.
    Huettmann, A.
    Glunz, A.
    Fuchs, M.
    Engert, A.
    HAEMATOLOGICA, 2016, 101 : 5 - 6
  • [29] Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
    Sven Borchmann
    Horst Müller
    Heinz Haverkamp
    Christian Baues
    Jana Marková
    Andreas Hüttmann
    Axel Glunz
    Michael Fuchs
    Peter Borchmann
    Andreas Engert
    Leukemia, 2019, 33 : 439 - 446
  • [30] Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
    Borchmann, Sven
    Mueller, Horst
    Haverkamp, Heinz
    Baues, Christian
    Markova, Jana
    Huettmann, Andreas
    Glunz, Axel
    Fuchs, Michael
    Borchmann, Peter
    Engert, Andreas
    LEUKEMIA, 2019, 33 (02) : 439 - 446
12345